In summary, artesunate acts by reducing M1 macrophage activation and suppressing the RIPK1/RIPK3/MLKL signaling cascade through the downregulation of Mincle expression, thereby diminishing the inflammatory response and necroptosis, which contributes to improvement of renal injury in AKI. Here, RIPK1 is linked to acute kidney injury.